Navigation Links
BioMarin to Present at the Bank of America Healthcare Conference
Date:5/7/2008

NOVATO, Calif., May 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Healthcare Conference in Las Vegas on Wednesday, May 14, 2008 at 1:20 p.m. PT.

Interested parties may access a live audio webcast of the presentation via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the presentation will be archived on the site for at least one week following the presentation.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.; Bank of America
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Announces First Quarter 2008 Financial Results
2. BioMarin to Present at the Morgan Stanley Healthcare Conference
3. BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)
4. BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
5. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
9. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
10. BioMarin to Present at the BioCentury NewsMakers Conference
11. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm ... stem cell technologies for neurodegenerative diseases, announced today that ... Alliance for Regenerative Medicine,s (ARM) 5 th Annual Cell ... at 09:40 EDT in Boston . ... Chief Medical Officer & Chief Operating Officer, will participate in ...
(Date:4/19/2017)... ... April 18, 2017 , ... The Vibrating Orifice Aerosol ... for generating monodisperse droplets of known diameters for research applications such as for ... particles by drying monodisperse droplets. , The VOAG requires forcing liquid out ...
(Date:4/19/2017)... ... April 18, 2017 , ... Alisa Wright, founder and ... Awards from the Purdue College of Pharmacy in Lafayette, Indiana. , The Distinguished ... for achievements in their careers and other scientific endeavors. , Wright began her ...
(Date:4/19/2017)... ... 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 ... Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. ... assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):